tetano
Editor, Senior Moderator
PLoS One
. 2024 May 13;19(5):e0303420.
doi: 10.1371/journal.pone.0303420. eCollection 2024. Baseline characteristics of SARS-CoV-2 vaccine non-responders in a large population-based sample
Ashraf Yaseen[SUP] 1 [/SUP], Stacia M DeSantis[SUP] 1 [/SUP], Rachit Sabharwal[SUP] 1 [/SUP], Yashar Talebi[SUP] 1 [/SUP], Michael D Swartz[SUP] 1 [/SUP], Shiming Zhang[SUP] 1 [/SUP], Luis Leon Novelo[SUP] 1 [/SUP], Cesar L Pinzon-Gomez[SUP] 1 [/SUP], Sarah E Messiah[SUP] 2 3 [/SUP], Melissa Valerio-Shewmaker[SUP] 4 [/SUP], Harold W Kohl 3rd[SUP] 5 6 [/SUP], Jessica Ross[SUP] 1 [/SUP], David Lakey[SUP] 7 8 [/SUP], Jennifer A Shuford[SUP] 9 [/SUP], Stephen J Pont[SUP] 9 [/SUP], Eric Boerwinkle[SUP] 1 [/SUP]
Affiliations
Introduction: Studies indicate that individuals with chronic conditions and specific baseline characteristics may not mount a robust humoral antibody response to SARS-CoV-2 vaccines. In this paper, we used data from the Texas Coronavirus Antibody REsponse Survey (Texas CARES), a longitudinal state-wide seroprevalence program that has enrolled more than 90,000 participants, to evaluate the role of chronic diseases as the potential risk factors of non-response to SARS-CoV-2 vaccines in a large epidemiologic cohort.
Methods: A participant needed to complete an online survey and a blood draw to test for SARS-CoV-2 circulating plasma antibodies at four-time points spaced at least three months apart. Chronic disease predictors of vaccine non-response are evaluated using logistic regression with non-response as the outcome and each chronic disease + age as the predictors.
Results: As of April 24, 2023, 18,240 participants met the inclusion criteria; 0.58% (N = 105) of these are non-responders. Adjusting for age, our results show that participants with self-reported immunocompromised status, kidney disease, cancer, and "other" non-specified comorbidity were 15.43, 5.11, 2.59, and 3.13 times more likely to fail to mount a complete response to a vaccine, respectively. Furthermore, having two or more chronic diseases doubled the prevalence of non-response.
Conclusion: Consistent with smaller targeted studies, a large epidemiologic cohort bears the same conclusion and demonstrates immunocompromised, cancer, kidney disease, and the number of diseases are associated with vaccine non-response. This study suggests that those individuals, with chronic diseases with the potential to affect their immune system response, may need increased doses or repeated doses of COVID-19 vaccines to develop a protective antibody level.
. 2024 May 13;19(5):e0303420.
doi: 10.1371/journal.pone.0303420. eCollection 2024. Baseline characteristics of SARS-CoV-2 vaccine non-responders in a large population-based sample
Ashraf Yaseen[SUP] 1 [/SUP], Stacia M DeSantis[SUP] 1 [/SUP], Rachit Sabharwal[SUP] 1 [/SUP], Yashar Talebi[SUP] 1 [/SUP], Michael D Swartz[SUP] 1 [/SUP], Shiming Zhang[SUP] 1 [/SUP], Luis Leon Novelo[SUP] 1 [/SUP], Cesar L Pinzon-Gomez[SUP] 1 [/SUP], Sarah E Messiah[SUP] 2 3 [/SUP], Melissa Valerio-Shewmaker[SUP] 4 [/SUP], Harold W Kohl 3rd[SUP] 5 6 [/SUP], Jessica Ross[SUP] 1 [/SUP], David Lakey[SUP] 7 8 [/SUP], Jennifer A Shuford[SUP] 9 [/SUP], Stephen J Pont[SUP] 9 [/SUP], Eric Boerwinkle[SUP] 1 [/SUP]
Affiliations
- PMID: 38739625
- DOI: 10.1371/journal.pone.0303420
Introduction: Studies indicate that individuals with chronic conditions and specific baseline characteristics may not mount a robust humoral antibody response to SARS-CoV-2 vaccines. In this paper, we used data from the Texas Coronavirus Antibody REsponse Survey (Texas CARES), a longitudinal state-wide seroprevalence program that has enrolled more than 90,000 participants, to evaluate the role of chronic diseases as the potential risk factors of non-response to SARS-CoV-2 vaccines in a large epidemiologic cohort.
Methods: A participant needed to complete an online survey and a blood draw to test for SARS-CoV-2 circulating plasma antibodies at four-time points spaced at least three months apart. Chronic disease predictors of vaccine non-response are evaluated using logistic regression with non-response as the outcome and each chronic disease + age as the predictors.
Results: As of April 24, 2023, 18,240 participants met the inclusion criteria; 0.58% (N = 105) of these are non-responders. Adjusting for age, our results show that participants with self-reported immunocompromised status, kidney disease, cancer, and "other" non-specified comorbidity were 15.43, 5.11, 2.59, and 3.13 times more likely to fail to mount a complete response to a vaccine, respectively. Furthermore, having two or more chronic diseases doubled the prevalence of non-response.
Conclusion: Consistent with smaller targeted studies, a large epidemiologic cohort bears the same conclusion and demonstrates immunocompromised, cancer, kidney disease, and the number of diseases are associated with vaccine non-response. This study suggests that those individuals, with chronic diseases with the potential to affect their immune system response, may need increased doses or repeated doses of COVID-19 vaccines to develop a protective antibody level.